who shouldn't take glp 1 Chart: in 8 Americans Now Use GLP-1 Drugs for Weight Loss Long-term Success of GLP-1s Hinges

Frontiers in Public Health , 11 , 1215817

Over time, pharmacological engineering enabled: Short-acting injectables (e.g., exenatide) Long-acting once-weekly injectables (liraglutide, semaglutide) Multi-target incretin therapies (tirzepatide) Oral peptide formulations and now oral small molecules The most recent breakthrough is the development of orally available GLP-1 receptor agonists, including: Orforglipron (Lilly) Elecoglipron (AstraZeneca) These compounds eliminate the need for injection and could dramatically expand accessibility and adherence in obesity and diabetes populations

PPA exposure produced pronounced oxidative stress and disruptions in lipid metabolism, whereas post-treatment with omega-3 or vitamin B12, administered individually or together, partially normalized antioxidant defenses, modulated inflammatory enzyme activity, and altered microbial profiles

Do not start GLP-1 medication without a licensed provider

Should a patient be unable to tolerate GI adverse events, a lower dose or alternative GLP-1 receptor agonist can be considered